Variation and outcomes of liver-reducing dietary regimens before bariatric surgery: a national retrospective cohort study

Sally Abbott, M.Res., Charlotte Price, Ph.D., Dimitrios J. Pournaras, Ph.D., Karen Coulman, Ph.D., on behalf of the British Obesity and Metabolic Surgery Society BariDIET Research Group

Specialist Weight Management Service, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
Research Centre for Intelligent Healthcare, Coventry University, Coventry, United Kingdom
Sigma, Coventry University, Frederick Lanchester Library, Coventry, United Kingdom
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
Bristol Weight Management and Bariatric Service, North Bristol NHS Trust, Southmead Hospital, Bristol, United Kingdom

Received 15 April 2022; accepted 16 October 2022

Abstract

Background: Liver-reducing diets (LRDs) are mandated prior to bariatric surgery, but there are no guidelines on their implementation.

Objective: To establish the variation and effectiveness of LRDs utilized in clinical practice.

Setting: A nationwide, multicenter, retrospective cohort study.

Methods: A total of 1699 adult patients across 14 bariatric centers in the United Kingdom were included. Multilevel logistic regression models were developed to examine factors predictive of 5% weight loss.

Results: Most centers (n = 9) prescribed an 800- to 1000-kcal diet, but the duration and formulation of diet was variable. Overall, 30.6% (n = 510) of patients achieved 5% weight loss during the LRD. After adjustment for preoperative weight, women had reduced odds (odds ratio [OR], .65; 95% confidence interval [CI], .48–.88; P = .005), while increasing age (OR, 1.01; 95% CI, 1.00–1.02; P = .043) and having type 2 diabetes (OR, 1.49; 95% CI, 1.16–1.92; P = .002) increased odds of 5% weight loss. A normal consistency food LRD (OR, .64; 95% CI, .42–.98; P = .041) and energy prescription of >1200 kcals/d (OR, .33; 95% CI, .13–.83; P = .019) reduced odds, while an LRD with a duration of 3 weeks (OR, 2.28; 95% CI, 1.02–5.09; P = .044) or greater increased odds of 5% weight loss.

Conclusions: There is wide variation in how LRDs are delivered in clinical practice, highlighting the need for an evidence-based consensus. Our findings suggest the optimal LRD before bariatric surgery contains 800 to 1200 kcals/d over a duration of 3 to 4 weeks. Further research is required to determine the optimal formulation of LRD and whether women may require a lower-energy LRD than men. (Surg Obes Relat Dis 2022; :1–7.) © 2022 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords: Liver-reducing diet; Low-energy diet; Very low–energy diet; Bariatric surgery; Nutrition; Preoperative optimization
Obesity is characterized by excess adipose tissue, which can result in nonalcoholic fatty liver disease (NAFLD) due to the exaggerated synthesis and deposition of triglycerides in hepatocytes [1]. Body mass index (BMI) has a significant positive correlation with liver steatosis [2] and compared with normal BMI; obesity increases the risk of developing NAFLD by 3.5-fold [3].

The prevalence of NAFLD among patients undergoing bariatric surgery is reported to be as high as 81% to 90% [4,5]. NAFLD presents an operative challenge for laparoscopic bariatric surgery, as liver retraction is necessitated to gain access to the stomach, and therefore bariatric centers around the world mandate a short-term preoperative liver-reducing diet (LRD).

LRDs facilitate the depletion of glycogen and lipid stores in the liver, resulting in a reduction in liver volume and improved liver flexibility [6]. LRDs also result in rapid weight loss which reduces visceral adiposity [7], enabling improved access to the stomach. LRDs can affect patient outcomes through a variety of mechanisms, including reduction in surgeons’ perceived complexity of the procedure [8], improved whole-body insulin sensitivity [9], and possible reduction in the risk of postoperative complications [10].

LRDs are supported by the Guidelines for Perioperative Care in Bariatric Surgery in the Enhanced Recovery After Surgery (ERAS) Society Recommendations [11], as there is a significant positive correlation between total weight loss and hepatic volume reduction during LRDs prior to bariatric surgery [8] and therefore weight loss is a pragmatic marker of liver volume reduction.

It is common practice for patients undergoing bariatric surgery to be supported toward a 5% weight loss in the immediate period before surgery, to reduce hepatic volume [12]. European Society for Clinical Nutrition and Metabolism Guidelines on Clinical Nutrition in Liver Disease [13] recommend low-energy diets as an effective intervention in achieving a weight loss at least 5% and a significant improvement in liver steatosis in NAFLD. Among patients undergoing bariatric surgery, a 5% weight loss during preoperative dietary regimens results in hepatic volume reductions of between 15.6% [8] and 23.0% [14].

A systematic review [12] synthesized the findings of 8 randomized controlled trials (RCTs) to examine the effectiveness of LRDs in achieving a 5% weight loss. LRDs of 700 to 1050 kcal/d over a minimum duration of 3 weeks supported the attainment of a 5% weight loss. However, definitive evidence-based conclusions were unable to be drawn from this study, due to the limited number of trials and the heterogenous nature of the LRD interventions.

There is high variability in how LRDs are delivered within and between multiple countries across the world [15–18]. This reflects the lack of conclusive evidence on the most optimal type, content, or duration of LRD [19], resulting in European [20] and US [21] clinical practice guidelines being unable to make evidence-based recommendations on the delivery of LRDs. Hence, the aim of this study was to establish the variation in, and weight loss outcomes of, LRDs currently used in clinical practice across multiple bariatric centers in the United Kingdom (UK).

Methods

Study population

We conducted a UK multicenter retrospective cohort study examining weight loss outcomes from LRDs before bariatric surgery. An open invitation was sent to dietitians, inviting them to nominate their bariatric center to contribute data to the study. The invitation was sent to members of a closed online discussion forum (Google Group) for registered dietitians working in bariatric services in the UK. To participate in the study, centers were required to have access to patient records that detailed the prescribed LRD and weight before and after LRD at the individual patient level.

All adult patients (≥18 years of age) who underwent a primary bariatric procedure funded by the National Health Service (NHS) between January 1 and December 31, 2019, were eligible for inclusion. For adults to be eligible for NHS funded bariatric surgery in the UK, a supervised weight management program must have been undertaken for 6 to 12 months with support from a specialist multidisciplinary team (MDT) and have a starting BMI ≥40 kg/m² or between 35 and 40 kg/m² with an obesity-related co-morbidity [22]. Patients were excluded if LRD intervention or weight outcome data were missing from the patient records.

Data collection

Data were collected at the site level from existing patient records and included patient demographic (sex, age, ethnicity), type 2 diabetes (T2D) status, LRD intervention (prescribed energy intake [kcal]), formulation, duration, and whether patients could choose which diet they followed), and anthropometrics (weight, BMI) before starting the LRD and on the day of surgery, when the LRD ended. In UK clinical practice, patients undergoing bariatric surgery may experience short-notice surgery cancellations, leading to prolongation of the LRD. Therefore, any extension to the duration of the LRD was also recorded, including reasons. Data were anonymized by the participating sites before transferring the data to the lead researcher for analysis.

Weight loss was used as a pragmatic surrogate marker of liver size reduction. A ≥5% weight loss is achievable via nutritional intervention and results in clinical improvements in hepatic steatosis [13] and, hence, the primary outcome was attainment of 5% weight loss on the day of surgery.

Ethical approval was granted by Coventry University Ethics Committee, Coventry, UK (PI30160).
Data analysis

All analyses were undertaken using SPSS version 26. Descriptive statistics were used to explore individual patient characteristics and intervention factors associated with achieving 5% weight loss. χ² tests were used to explore associations between the different elements of the dietary intervention and the achievement of 5% weight loss. Since data were collected across several different bariatric centers, multilevel logistic regression models were developed to investigate factors predictive of 5% weight loss, adjusting for clustering, since patients are clustered (i.e., grouped) within centers.

In the first step, a null model was fitted to the data. Bariatric center was included in the model as a random effect since the likelihood ratio test statistic was significant at the 5% level. This indicates that differences between bariatric centers account for some of the variability in attainment of 5% weight loss before surgery. Individual level characteristics were then added as fixed effects to the model and removed one-by-one using a manual backward elimination approach if they did not achieve statistical significance based on a cut-point of $P = .05$. These included age (yr), sex (male/female), T2D status at baseline (yes/no), weight at baseline (kg), ethnicity and whether the diet was extended (yes/no). Finally, elements of the LRD were added to the model and removed one at a time according to the above strategy. These included daily energy prescription (kcals), recommended diet duration (wk), diet formulation, and whether the patient was given a choice of diet (yes/no). The choice of diet was effectively a bariatric center-level variable (level 2) since the bariatric centers in the study either gave patients a choice or not. The other LRD elements were almost level-2 variables, with very little within-center variability.

Results

Fourteen out of 55 NHS funded bariatric centers in the UK participated in the study. A total of 1817 patients were eligible of which 1669 were included in the analysis: 5.30 kg (95% confidence interval [CI], 5.06–5.54) and 510 patients (30.6%) achieved 5% weight loss (Table 2). The remaining centers (n = 7) gave patients the autonomy to choose their LRD formulation, which could also include meal replacement formulations. The duration of LRD was standardized for all patients in 7 centers, regardless of patients’ BMI, with 6 centers prescribing a 2-week duration and 1 center prescribing a 3-week duration. Across the other bariatric centers (n = 7), the duration of the LRD was dependent upon BMI, whereby patients with a higher BMI of ≥50 or ≥60 kg/m² were prescribed a longer duration of LRD, which ranged from 3 to 12 weeks.

Most patients undertook the LRD for the prescribed duration, but a small number of patients underwent a prolonged LRD (n = 129, 7.7%) for a median duration of 14.5 days (IQR, 7–28 days). Reasons for a prolonged duration of LRD were mainly due to rescheduling of surgery dates due to bed capacity or surgeon availability (n = 106).

Weight loss outcomes

The mean weight loss between baseline and surgery was 5.30 kg (95% confidence interval [CI], 5.06–5.54) and 510 patients (30.6%) achieved 5% weight loss (Table 2).

Results of the multilevel logistic regression model to investigate 5% weight loss are shown in Table 3. The null model showed that there was a significant random effect for bariatric center ($P = .039$), but this effect disappeared after accounting for characteristics of the patients and the LRD. After adjusting for weight before surgery, patient factors that improved the odds of 5% weight loss included increasing age, male sex, and having T2D. In particular, the odds of achieving 5% weight loss for women were around 0.6 times the odds for men after accounting for the

| Characteristic | Value |
|---------------|-------|
| Age (yr), mean (SD) | 46.8 (11.1) |
| Male, n (%) | 344 (20.6%) |
| Ethnicity, n (%) | |
| White | 1367 (81.9%) |
| Black | 60 (3.6%) |
| South Asian | 50 (3.0%) |
| Other | 62 (3.7%) |
| Unknown | 130 (7.8%) |
| Diabetes, n (%) | |
| No diabetes | 1207 (72.3%) |
| Type 2 diabetes | 447 (26.8%) |
| Type 1 diabetes | 15 (9%) |
| Weight (kg), mean (SD) | 130.6 (25.6) |
| BMI (kg/m²), mean (SD) | 46.8 (7.8) |

SD = standard deviation; BMI = body mass index.

Table 1
Baseline characteristics of participants (n = 1669)
other factors in the model (adjusted odds ratio [OR], .648; 95% CI, .479–.875; $P = .005$). Elements of the LRD impacting 5% weight loss included the diet formulation, prescribed energy intake, and the diet duration. Those on a normal consistency food diet were less likely to achieve 5% weight loss compared with those on a liquid consistency diet (adjusted OR, .643; 95% CI, .421–.982; $P = .041$), and the odds of achieving 5% weight loss increased with weeks on diet, with 3 weeks or more showing significant benefit over just 1 week.

Table 2
5% weight loss by dietary intervention (n = 1669)

| Dietary intervention | Total | Achieved 5% weight loss, n (%) | $P$ value* |
|----------------------|-------|-------------------------------|------------|
| All                  | 1669  | 510 (30.6%)                   | -          |
| Choice of diet       |       |                               |            |
| Yes                  | 682   | 280 (41.1%)                   | $.001      |
| No                   | 987   | 230 (23.3%)                   |            |
| Kcals                |       |                               |            |
| <800                 | 65    | 20 (30.8%)                    | $.001      |
| 800–1000             | 985   | 381 (38.7%)                   |            |
| 1000–1200            | 512   | 93 (18.2%)                    |            |
| >1200                | 107   | 16 (15.0%)                    |            |
| Formulation          |       |                               | $.001      |
| Nonsolid food        | 1136  | 290 (25.5%)                   |            |
| Food                 | 227   | 68 (30.0%)                    |            |
| Meal replacements    | 73    | 37 (50.7%)                    |            |
| Meal replacements + food | 233 | 115 (49.4%) | |
| Duration             |       |                               | $.001      |
| 1 wk                 | 88    | 12 (13.6%)                    |            |
| 2 wk                 | 1160  | 302 (26.0%)                   |            |
| 3 wk                 | 194   | 76 (39.2%)                    |            |
| 4 wk                 | 170   | 87 (51.2%)                    |            |
| >5 wk                | 57    | 33 (57.9%)                    |            |

* $\chi^2$ test for independence.

Table 3
Results of random effects logistic regression model (n = 1669)

| Fixed effects | Coefficient | Adjusted odds ratio (95% CI) | $P$ value* |
|---------------|-------------|------------------------------|------------|
| Intercept     | -2.571      | .076 (.019, .305)            | $.001      |
| Age           | .011        | 1.011 (1.000, 1.022)         | .043       |
| Sex: female   | -.334       | .648 (.479, .875)            | .005       |
| Diabetes: yes | .401        | 1.493 (1.159, 1.924)         | .002       |
| Baseline weight (kg) | .007 | 1.007 (1.002, 1.013) | .011 |
| Diet extended: yes | .569 | 1.766 (1.139, 2.739) | .011 |
| Kcals <800    | -           | -                            | -          |
| 800–1000      | .144        | 1.155 (.578, 2.305)          | .683       |
| 1000–1200     | -.627       | .534 (.257, 1.113)           | .094       |
| >1200         | -1.099      | .333 (.133, .832)            | .019       |
| Diet formulation |       |                              |            |
| Nonsolid food | -           | -                            | -          |
| Food          | -.441       | .643 (.421, .982)            | .041       |
| Meal replacements | .220 | 1.246 (.693, 2.240) | .461 |
| Meal replacements + food | .283 | 1.327 (.856, 2.057) | .206 |
| Duration      |       |                              |            |
| 1 wk          | -           | -                            | -          |
| 2 wk          | .478        | 1.613 (.794, 3.277)          | .186       |
| 3 wk          | .825        | 2.282 (1.023, 5.086)         | .044       |
| 4 wk          | 1.091       | 2.977 (1.283, 6.905)         | .011       |
| >5 wk         | 1.254       | 3.504 (1.331, 9.222)         | .011       |
| Random effect |             |                              |            |
| Variance (95% CI) | .036 | (.003, .411) | .415 |

CI = confidence interval.
Discussion

This is the first multicenter study on a national scale to examine the outcomes of a range of LRDs utilized in clinical practice before bariatric surgery. Previous research has shown that a ≥5% weight loss before bariatric surgery is shown to reduce liver volume by up to 23.0% [8,14]. Our findings suggest less than a third (30.6%) of patients undertaking an LRD before bariatric surgery have a ≥5% weight loss. We also found that there is now greater variation in the formulation and energy prescription of LRDs utilized in UK clinical practice, compared with 2012 [18].

Variation in LRD interventions

The duration of LRDs utilized in today’s clinical practice are akin to 2012 practices [18], whereby three quarters of patients (76.7%) in our study were prescribed a shorter duration diet (≤2 weeks), compared with 75% of bariatric centers in 2012. However, we report that the prescribed energy and formulation of LRDs has become more variable in today’s practice. In 2012, all centers that provided data prescribed a low-energy diet (LED) of 800 to 1000 kcals/d and the most common formulation of LRD was normal consistency food (59%). In our study, the most common formulation of LRD was liquid consistency food (68.1%), and there is now more variation in energy prescription. The heterogenous nature of LRD interventions within our study is not surprising, given that international clinical guidelines [20,21] do not specify recommendations on how LRDs should be delivered in practice.

Patient characteristics

Men characteristically have a higher body mass (kg) and greater fat free mass (%) than women [23,24], and therefore men have a higher resting energy expenditure (REE) [25]. A 16% greater weight loss has been reported among men compared with women when following a fixed LED of 810 kcals for 8 weeks [23]. None of the bariatric centers included in our study prescribed a lower-energy LRD for women compared with men, and this may explain our findings that women had a reduced odds of attaining a 5% weight loss, suggesting that women should be prescribed a lower-energy prescription compared with men.

Patients with T2D had greater odds of achieving a 5% weight loss during the LRD compared with those without diabetes. In a large retrospective cohort study from the US and Canada [26], patients achieving a >5% or >10% weight loss were also more likely to have T2D (P ≤ .001). We acknowledge that we did not collect data on T2D medications or glycemic control in our study, and therefore further research is required to examine these findings, in particular whether diabetes pharmacotherapy, such as GLP-1 receptor agonists, may explain greater weight loss among patients with T2D in the LRD period.

LRD energy prescription

These findings support the use of energy restriction of <1200 kcals/d, either in the form of a LED (800–1200 kcals/d) or very low–energy diet (VLED) (<800 kcals/d). However, we would argue that in clinical practice, LED energy prescriptions may be the preferable recommendation for patients. In a parallel randomized trial of a 3-week VLED versus LED before bariatric surgery [8], both interventions significantly decreased hepatic volume (−15.6%, P = .045; −12.3%, P = .045, respectively) and, moreover, there was no difference in the reduction of hepatic volume between groups (P = .409). In addition, a significantly higher proportion of participants in the VLED group reported adverse events of dizziness and physical weakness (P ≤ .05). Ketonuria measurements have also indicated that only 26% of patients were compliant with a VLED before bariatric surgery, suggesting difficulties with adherence at this level of energy restriction [27].

A LED may be favorable to minimize the transient increases in liver enzymes that have been reported during LRDs prior to bariatric surgery. In a randomized controlled trial of a 3-week VLED (800 kcals/day) versus LED (1200 kcals/day) LRD, after adjustment, there was a significant increase in ALT in the VLED group of 12.3 U/L (P = .001), but not in the LED group (P = .108). Although enzyme elevation is transient and is shown to normalize after a period of weight stability [28], a less restrictive LED may be favorable over a VLED, to minimize exacerbation of liver injury during the preparatory period before surgery.

LRD formulation

Patients following a normal consistency food LRD had reduced odds of attaining a 5% weight loss, compared with a liquid consistency food diet. It is proposed that liquid consistency food formulations of LRDs are more restricted and are more convenient to prepare than conventional food. Indeed, in a RCT of a liquid versus normal consistency food LRD [27], visceral fat was significantly lower at 2 weeks for a liquid (−20.6%) compared with the normal consistency food (−28%) LRD (P = .041).

However, during a liquid LRD formulation self-reported hunger was significantly higher among the liquid versus normal consistency food-based diet groups at 1 week (P = .004) and 2 weeks (P ≤ .0001) [27]. Inhibitory control is impaired in adults with obesity [29] and hence solid or more viscous formulations of meal replacements, or a combined meal replacement + food formulation, may be preferable to manage hunger levels and increase compliance.

LRD duration

Compared with a 1-week LRD, an LRD of ≥3 weeks increases the odds of attaining 5% weight loss. Previous research has examined changes in liver volume during a
6-week VLED before bariatric surgery, with measurements obtained at 2, 4, and 6 weeks [30]. It was concluded that a 4-week duration is the ideal period for a LRD, since the liver volume reached a maximum reduction at 4 weeks, suggesting decreasing compliance to the LRD between 4 and 6 weeks. However, no measurements were taken at the 3-week timepoint to distinguish where 3 or 4 weeks of LRD is an optimal duration. An LRD of ≥5 weeks duration may be unnecessary and could negatively impact on patient compliance [31], negating any potential benefit of an extended duration of LRD.

**Strengths and limitations**

The main strengths of this study are the large sample size across multiple centers and the generalizability of findings to international clinical practice, as our population was reflective of the international demographic characteristics of patients undergoing bariatric surgery [32]. Limitations of this study include the retrospective approach to data collection, which meant a small proportion of the eligible population (8.1%) were excluded from the analysis due to missing data; it was not feasible to obtain measurements of changes to liver volume or to obtain data on the macronutrient composition of the LRDs utilized.

The focus of our study was on the preoperative period only, hence we did not examine whether weight loss during LRDs influences postoperative outcomes. Although individual studies examining LRDs and postoperative complications show conflicting findings, ERAS Society Recommendations [11] concluded from the available literature that there is a moderate level of evidence that LRDs do reduce postoperative complications. However, owing to mortality event rates being so low following bariatric surgery it is difficult to ascertain whether preoperative weight loss during LRDs is associated with mortality risk [33].

A 5% weight loss is recommended to reduce liver steatosis in NAFLD [13], however there are limited studies within the bariatric surgery population [8,14] examining whether this is an optimal weight loss to significantly reduce liver volume during LRDs and whether this is indeed associated with a reduction in postoperative complications. Hence, measurements of changes in liver volume and postoperative data on a large sample of patients is required to confirm that a 5% weight loss is the appropriate recommendation within this population group.

**Conclusion**

There is a wide variation in the way LRDs are delivered in clinical practice, suggesting that a consensus on how LRDs should be delivered in clinical practice is needed. Our findings support that a liquid consistency food, meal replacement or a combined meal replacement + normal consistency food formulation, containing 800 to 1200 kcals/d, for a duration of 3 to 4 weeks is the most effective LRD for 5% weight loss before bariatric surgery. Women may require a lower-energy LRD than men, and this should be examined by further research. Finally, given the wide variation in how LRDs were delivered, there is a need for further prospective, high-quality research to confirm our findings and determine more precisely which formulation of LRD is most effective before an evidence-based consensus on LRDs for clinical practice can be reached to standardize patient care.

**Acknowledgments**

This work was supported by the British Dietetic Association Obesity Specialist Group (Research, Audit, and Evaluation grant, 2020). The authors give special thanks to all the members of the British Obesity and Metabolic Surgery Society BarIDET Research Group (Kate Colban, Sarah Matthias, Lisa Cant, Michelle Soobayah, Maisie Rowley, Lucy Rout, Guy Holt, Kate Waller, Charlotte Birkett, Melanie Langley, Tom Chapman, Kate Rust, Abi Johnson, Priscila Goncalvez, Vanessa Osborne, Emily Cooper, Emma Little, Helen Kingett, Amy Kirk, Nausheen Hamid, Dervla Kavanagh, Georgia Windrass, Emma White, Madeleine Williams, Lauren Bateman, Natalie Conway, and Aimee Newton), who made this study possible by carrying out data collection within their respective bariatric units.

**Disclosures**

S. Abbott receives speaker honoraria from Johnson & Johnson for educational events. D.J. Pournaras has been funded by the Royal College of Surgeons of England. He receives consulting fees from Johnson & Johnson and payments for lectures, presentations, and educational events from Johnson & Johnson, Medtronic, and Novo Nordisk. K. Coulman, clinical lecturer (ICA-CL-2018-04-ST2-008), is funded by Health Education England/National Institutes for Health Research (NIHR), the Bristol Centre for Surgical Research, and the NIHR Bristol and Weston Biomedical Research Centre (various grants) at the University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS, the UK Department of Health and Social Care, Royal College of Surgeons of England, or Medical Research Council.

**Supplementary materials**

Supplementary material associated with this article can be found, in the online version, at https://doi.org/10.1016/j.soard.2022.10.027.
References

[1] Parker R. The role of adipose tissue in fatty liver diseases. Liver Res 2018;2(1):35–42.
[2] Fan R, Wang J, Du J. Association between body mass index and fatty liver risk: a dose-response analysis. Sci Rep 2018;8(1):15723.

[3] Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev 2016;17(6):510–9.

[4] Soresi M, Cabibi D, Giglio R, et al. The prevalence of NAFLD and fibrosis in bariatric surgery patients and the reliability of noninvasive diagnostic methods. Biomed Res Int 2020;2020:5023157.

[5] Losekann A, Weston AC, de Carli LA, Espindola MB, Edholm D, Kullberg J, Haenni A, et al. The prevalence of NAFLD and dependent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev 2018;19(11):1148–59.

[6] Edholm D, Kulberg J, Haenni A, et al. Preoperative 4-week low-calorie diet reduces liver volume and intrahepatic fat, and facilitates laparoscopic gastric bypass in morbidly obese Surg Obes Relat Dis 2011;7(4):480–5.

[7] Collins J, McCloskey C, Titchner R, Goodpaster B, Hoffman M, Hauser D, et al. Preoperative weight loss in high-risk obese bariatric patients: a computed tomography-based analysis. Surg Obes Relat Dis 2011;7(4):480–5.

[8] Gils Contreras A, Bonada Sanjaume A, Montero Jaime M, et al. Effects of two preoperative weight loss diets on hepatic volume, metabolic parameters, and surgical complications in morbidly obese bariatric surgery candidates: a randomized clinical trial. Obes Surg 2018;28(12):3756–68.

[9] Pournaras DJ, Nygren J, Hagström-Toft E, Arner P, le Roux CW, Thorell A. Improved glucose metabolism after gastric bypass: evolution of the paradigm. Surg Obes Relat Dis 2016;12(8):1457–65.

[10] van Nieuwenhove Y, Dambrauskas Z, Campillo-Soto A, et al. Preoperative nutritional management of obese patients, subjected to bariatric surgery. Arq Gastroenterol 2018;2(1):35–42.

[11] Holderbaum MS, Buss C. Dietary management in the immediate preoperative period of bariatric surgery: a national overview: bariatric preoperative diets. Obes Surg 2018;28(6):1688–96.

[12] Baldry EL, Leeder PC, Idris IR. Pre-operative dietary restriction for patients undergoing bariatric surgery in the UK: observational study of current practice and dietary effects. Obes Surg 2013;23(3):416–21.

[13] Kim JJ, Rogers AM, Ballem N, Schirmer B. ASMSB updated position statement on insurance mandated preoperative weight loss requirements. Surg Obes Relat Dis 2016;12(5):955–9.

[14] di Lorenzo N, Antoniou SA, Batterham RL, et al. Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP. Surg Endosc 2020;34(6):2332–52.

[15] Mechanick JI, Apovian C, Brehm S, et al. Clinical Practice Guidelines for The Preoperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 update: cosponsored by American Association of Clinical Endocrinologists/ American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists – Executive Summary. Endocr Pract 2019;25(12):1346–59.

[16] National Institute for Care and Health Excellence (NICE) [Internet]. London: The Institute; Published 27 Nov 2014 [updated 2022 Sep 8; cited 2022 September 11]. Obesity: identification, assessment and management Clinical guideline [CG189] [about 56 screens]. Available from: https://www.nice.org.uk/guidance/CG189/resources/obesity-identification-assessment-and-management-pdf-35109821097925.

[17] Christensen P, Meindert Larsen T, et al. Men and women respond differently to rapid weight loss: metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW). Diabetes Obes Metab 2018; 20(12):2840–51.

[18] Bredella MA. Sex differences in body composition. Adv Exp Med Biol 2017;1043:9–27.

[19] Nocito M, Ballard T, Shaw J. Human energy requirements: report of a joint FAO/WHO/UNU Expert Consultation. Food Nutr Bull 2005;26(1):166.

[20] Sun Y, Liu B, Smith JK, et al. Association of preoperative body weight and weight loss with risk of death after bariatric surgery. JAMA Netw Open 2020;3(5):e204805.

[21] Faria SL, Faria OP, Cardeal MDA, Ito MK. Effects of a very low calorie diet in the preoperative stage of bariatric surgery: a randomized trial. Obes Surg 2015;11(1):230–7.

[22] Gasteyer C, Larsen TM, Vercruysse F, Astrup A. Effect of a dietary-induced weight loss on liver enzymes in obese subjects. Am J Clin Nutr 2008;87(5):1141–7.

[23] Lavagnino L, Arnone D, Cao B, Soares JC, Selvaraj S. Inhibitory control in obesity and binge eating disorder: a systematic review and meta-analysis of neurocognitive and neuroimaging studies. Neurosci Biobehav Rev 2016;68:714–26.

[24] González-Pérez J, Sánchez-Lenheer S, Delgado AR, et al. Clinical impact of a 6-week preoperative very low calorie diet on body weight and liver size in morbidly obese patients. Obes Surg 2013;23(10):1624–31.

[25] Colles SL, Dixon JB, Marks P, Strauss BJ, O'Brien PE. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr 2006;84(2):304–11.

[26] Ramos A, Kow L, Brown W, et al. 5th IFSO Global Registry Report [monograph on the Internet]. Reading, U.K.: Dendrite Clinical Systems Ltd:2019 [cited 2022 Mar 30]. Available from: https://www. ifso.com/pdf/5th-ifso-global-registry-report-september-2019.pdf.

[27] Roman M, Monaghan A, Serraino GF, et al. Meta-analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes. Br J Surg 2019;106(3):181–9.